Lowest-Rated Stocks NASDAQ:NKTR Nektar Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. $3.75 -0.05 (-1.32%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$3.67▼$3.8450-Day Range$3.17▼$4.7252-Week Range$3.02▼$19.37Volume2.37 million shsAverage Volume3.77 million shsMarket Capitalization$698.51 millionP/E RatioN/ADividend YieldN/APrice Target$13.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Nektar Therapeutics MarketRank™ ForecastAnalyst RatingHold2.08 Rating ScoreUpside/Downside251.1% Upside$13.17 Price TargetShort InterestHealthy9.47% of Shares Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.83Based on 5 Articles This WeekInsider TradingSelling Shares$334.28 K Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.31) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.05 out of 5 starsMedical Sector275th out of 1,428 stocksPharmaceutical Preparations Industry131st out of 682 stocks 3.0 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 3 buy ratings, 7 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.17, Nektar Therapeutics has a forecasted upside of 251.1% from its current price of $3.75.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.47% of the outstanding shares of Nektar Therapeutics have been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 1.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 2.1 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $334,277.00 in company stock.Percentage Held by InsidersOnly 2.91% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions93.08% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($2.31) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.Read More NKTR Stock News HeadlinesJuly 2, 2022 | marketwatch.comNektar Therapeutics Finance And Operations Chief to DepartJuly 1, 2022 | seekingalpha.comNektar promotes internal executive to CFO roleJuly 3, 2022 | Tradewins (Ad)Protect Your Trading Account With Options!This might be the opposite of what you’ve heard, but the real risk in the market now lies with stock trading… “Options Trading Made Easy” by expert Chuck Hughes will show you how the nature of options trading gives you the chance to profit no matter which way the market trends! Get the e-book today! July 1, 2022 | nasdaq.comNektar Therapeutics Promotes Chief Accounting Officer Jillian Thomsen To CFOJuly 1, 2022 | finance.yahoo.comNektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial OfficerJune 24, 2022 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Shares Up 6.5%June 12, 2022 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Receives $9.09 Consensus Price Target from BrokeragesMay 31, 2022 | bizjournals.comNektar Therapeutics plans layoffs for Huntsville locationJuly 3, 2022 | Base Camp Trading (Ad)Make Sure Your Alarm Is Set…This early morning trade is constantly overlooked, but those who use it are retiring early! Hi, I’m trading expert Dave Aquino and with my new guide, “How To Master The Retirement Trade”, you could be taking advantage of it as well! The trade starts at 9:30EST…don’t be late! Get a copy here!May 16, 2022 | finance.yahoo.comIs Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?May 5, 2022 | markets.businessinsider.comNektar Therapeutics Reports First Quarter 2022 Financial ResultsMay 5, 2022 | nasdaq.comNektar Therapeutics Q1 Loss decreases, beats estimatesApril 28, 2022 | finance.yahoo.comNektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 27, 2022 | finance.yahoo.comBristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?April 26, 2022 | benzinga.comAfter Bristol Myers Cuts Ties, Nektar Implements Cost RestructuringApril 25, 2022 | reuters.comNektar to cut over 500 jobs following cancer drug failureApril 25, 2022 | seekingalpha.comNektar Therapeutics unveils restructuring plan, laying off 70% of its workforceApril 25, 2022 | bizjournals.comNektar to cut almost 500 jobs, sublease some Bay Area space after clinical trial failuresApril 25, 2022 | finance.yahoo.comNektar Therapeutics Announces Strategic Reorganization Plan and Corporate OutlookApril 25, 2022 | finance.yahoo.comNektar to cut 500 jobs, sublease some Bay Area space after clinical trial failuresApril 25, 2022 | seekingalpha.comNektar cancer drug improves anti-tumor effect of CAR T drugsApril 18, 2022 | seekingalpha.comNektar stock slumps 36% on Goldman Sachs downgrade following bempeg program terminationApril 18, 2022 | benzinga.comMid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares SlideApril 18, 2022 | msn.comWhy Nektar Shares Are Down Almost 35%April 18, 2022 | markets.businessinsider.comExpert Ratings for Nektar TherapeuticsApril 18, 2022 | markets.businessinsider.comWhy Nektar Shares Are Down 35%April 18, 2022 | nz.finance.yahoo.comNektar (NKTR) Ends Bempeg Plus Opdivo Program on Study FailuresSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees740Year Founded1990Company Calendar Last Earnings5/05/2022Today7/03/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$13.17 High Stock Price Forecast$54.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+251.1%Consensus RatingHold Rating Score (0-4)2.08333333333333 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.670010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-523.84 million Net Margins-476.58% Pretax Margin-476.00% Return on Equity-65.64% Return on Assets-41.03% Debt Debt-to-Equity RatioN/A Current Ratio6.97 Quick Ratio6.82 Sales & Book Value Annual Sales$101.91 million Price / Sales6.85 Cash FlowN/A Price / Cash FlowN/A Book Value$3.68 per share Price / Book1.02Miscellaneous Outstanding Shares186,270,000Free Float180,853,000Market Cap$698.51 million OptionableOptionable Beta1.22 Social Links Nektar Therapeutics Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares. View analyst ratings for Nektar Therapeutics or view top-rated stocks. What is Nektar Therapeutics' stock price forecast for 2022? 12 Wall Street research analysts have issued 1 year price targets for Nektar Therapeutics' shares. Their NKTR stock forecasts range from $3.00 to $54.00. On average, they expect Nektar Therapeutics' stock price to reach $13.17 in the next twelve months. This suggests a possible upside of 251.1% from the stock's current price. View analysts' price targets for Nektar Therapeutics or view top-rated stocks among Wall Street analysts. How has Nektar Therapeutics' stock price performed in 2022? Nektar Therapeutics' stock was trading at $13.51 at the beginning of 2022. Since then, NKTR shares have decreased by 72.2% and is now trading at $3.75. View the best growth stocks for 2022 here. When is Nektar Therapeutics' next earnings date? Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Nektar Therapeutics. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.23. The biopharmaceutical company had revenue of $24.82 million for the quarter, compared to the consensus estimate of $24.89 million. Nektar Therapeutics had a negative net margin of 476.58% and a negative trailing twelve-month return on equity of 65.64%. The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.68) EPS. View Nektar Therapeutics' earnings history. Who are Nektar Therapeutics' key executives? Nektar Therapeutics' management team includes the following people: Mr. Howard W. Robin, CEO, Pres & Director (Age 69, Pay $2.14M)Mr. Gilbert M. Labrucherie J.D., Sr. VP, CFO & COO (Age 50, Pay $1.49M)Mr. Mark A. Wilson, Sr. VP, Gen. Counsel & Sec. (Age 50, Pay $798.26k)Dr. Jonathan Zalevsky Ph.D., Sr. VP & Chief R&D Officer (Age 47, Pay $1.16M) (LinkedIn Profile)Mr. John P. Northcott, Sr. VP & Chief Commercial Officer (Age 44, Pay $1.07M) (LinkedIn Profile)Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 56) (LinkedIn Profile)Mr. Robert Bacci, Sr. VP of HR and FacilitiesMs. Jennifer Ruddock, Sr. VP of Strategy & Corp. AffairsDr. Mary Tagliaferri L.Ac., M.D., Sr. VP & Exec. Clinical Fellow (Age 56)Dr. Brian L. Kotzin M.D., Sr. VP of Clinical Devel. & Head of Immunology (Age 73) What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees. Who are some of Nektar Therapeutics' key competitors? Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN) and Omeros (OMER). View all of NKTR's competitors. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." How do I buy shares of Nektar Therapeutics? Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $3.75. How much money does Nektar Therapeutics make? Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $698.51 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523.84 million in net income (profit) each year or ($2.670010) on an earnings per share basis. How many employees does Nektar Therapeutics have? Nektar Therapeutics employs 740 workers across the globe. When was Nektar Therapeutics founded? Nektar Therapeutics was founded in 1990. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for Nektar Therapeutics is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300. This page (NASDAQ:NKTR) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
